BioSpace

Register to watch FDA’s draft guidance on the validation of New Approach Methodologies (NAMs) is reshaping how nonclinical programs are designed and justified. This webinar explores how sponsors can apply NAMs to streamline development, improve human relevance, and support IND decision-making within a weight-of-evidence framework.

Subhendu Basu, CEO of Telum Therapeutics, and Roberto Díez, founder and COO of Telum Therapeutics.

Issued 4,444,445 new ordinary shares Priced at €2.70 per share, representing a 14.15% discount on the five-day VWAP and a 12.68% discount to the June 30 closing price The transaction has been structured as a capital increase without the issuance of warrants Proceeds will be used to advance the Company's clinical development programs and support other corporate initiatives The Social Impact Fund, managed by COFIDES, has committed to invest €25 million in future capital increases to support...

Healthcare leader begins next chapter of NKF's 75-year mission to improve kidney health and save lives NEW YORK, July 1, 2026 /PRNewswire/ -- Dr. Marc Hurlbert officially began serving as Chief Executive Officer of the National Kidney Foundation (NKF) today. The transition marks the beginning of a new chapter in the organization's more than 75-year history of improving kidney health and saving lives.

More than 1,400 patients enrolled across 9 clinical sites; analytical performance testing included 27 individual studies and over 10,000 PCR test cup runs Analytical data to support concurrent 510(k) submission with CLIA Waiver by Application for point-of-care settings, with submission targeted for Q3 2026 SALT LAKE CITY, July 1, 2026 /PRNewswire/ -- Co-Diagnostics, Inc.

NORTHFIELD, Ill., July 01, 2026 (GLOBE NEWSWIRE) -- Medline Inc. (“Medline”) (Nasdaq: MDLN) today announced that it plans to report second quarter 2026 financial results on Wednesday, August 5, 2026. A press release and supplemental materials will be issued before the market opens. The company will host a webcast and conference call at 9:30am ET/ 8:30am CT to discuss the financial results.

New Evidence Further Defines Distinct Clinical Considerations for Transcatheter Aortic Valve Replacement (TAVR) in Aortic Regurgitation (AR) and Advances Understanding of the Trilogy® System in Patients with Left Ventricular Assist Devices (LVADs) IRVINE, Calif., July 01, 2026 (GLOBE NEWSWIRE) -- JenaValve Technology, Inc., developer and manufacturer of the Trilogy Transcatheter Heart Valve (THV) System, today announced highlights from the New York Valves 2026 conference, where two...

SEATTLE, July 01, 2026 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced a symposium presentation highlighting clinical data from an investigator-sponsored, first-in-human study transplanting UP421, an allogeneic primary islet cell therapy engineered with Sana’s hypoimmune platform (HIP) technology, into a patient with type 1 diabetes without any immunosuppression.

After serving as interim Chief, Stella T. Chou, MD, will assume role on July 1 PHILADELPHIA, July 1, 2026 /PRNewswire/ -- Children's Hospital of Philadelphia (CHOP) is proud to announce the selection of Stella T. Chou, MD, as its new Chief of the Division of Hematology. Dr. Chou served as interim chief since August 2025 and will officially assume the role July 1, leading one of the nation's largest and highly ranked pediatric hematology programs.

TORONTO, July 1, 2026 /CNW/ - Apotex Health Corp. ("Apotex") (TSX: APTX), the largest Canadian-based pharmaceutical company, today announced the closing of its previously announced strategic transaction with Cumberland Pharmaceuticals Inc. ("Cumberland"), a U.S. biopharmaceutical company, to integrate Cumberland's U.S. branded businesses into Apotex.